Clinical Pharmacokinetics and Pharmacodynamics of Cholinesterase Inhibitors

被引：0
作者：
Michael W. Jann
Kara L. Shirley
Gary W. Small
机构：
[1] Mercer University,Department of Clinical and Administrative Sciences, Southern School of Pharmacy
[2] Albany College of Pharmacy,Department of Pharmacy Practice
[3] University of California,Department of Psychiatry and Biobehavioral Sciences, Center on Aging and Alzheimer’s Disease Research Center
[4] Mercer University,Southern School of Pharmacy
来源：
Clinical Pharmacokinetics | 2002年 / 41卷
关键词：
Cholinesterase; Fluvoxamine; Cholinesterase Inhibitor; Rivastigmine; Tacrine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Cholinesterase inhibitors are the ‘first-line’ agents in the treatment of Alzheimer’s disease. This article presents the latest information on their pharmacokinetic properties and pharmacodynamic activity.
引用
收藏
页码：719 / 739
页数：20
相关论文
共 249 条
[31]  
Askmark H.(1993)Comparison of the pharmacokinetics of E2020, a new compound for Alzheimer’s disease, in healthy young and elderly subjects J Clin Pharmacol 33 1086-5
[32]  
Aquilonius S.M.(1998)An evaluation of the pharmacokinetics of donepezil hydrochloride in patients with impaired hepatic function Br J Clin Pharmacol 46 51-60
[33]  
Madden S.(1998)An evaluation of the pharmacokinetics of donepezil hydrochloride in patients with impaired moderate to severe renal impairment Br J Clin Pharmacol 46 56-12
[34]  
Spaldin V.(2000)Rivastigmine, anew generation cholinesterase inhibitor for the treatment of Alzheimer’s disease Pharmacotherapy 20 1-7
[35]  
Park B.K.(1996)Safety/tolerability trial of SDZ 713 in patients with probable Alzheimer’s disease Life Sci 58 1201-411
[36]  
Nordberg A.(1998)Rivastigmine Drugs Aging 13 391-21
[37]  
Svensson A.L.(1999)Preferential cerebrospinal fluid acetylcholinesterase inhibition by rivastigmine in humans J Clin Psychopharmacol 19 513-50
[38]  
Wagstaff A.(1998)Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer’s disease Acta Neurol Scand 97 244-428
[39]  
McTavish D.(1996)The effects of renal and hepatic impairment on the disposition of acetylcholinesterase SDZ ENA 713 [abstract] Pharm Res 13 S-122
[40]  
Makela P.M.(2000)Galantamine Drugs 60 1095-8
12345678910